[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session .

1163 Patient-Reported Treatment Satisfaction with Oral Rivaroxaban Versus Standard Therapy in the Treatment of Acute Symptomatic Pulmonary Embolism

Program: Oral and Poster Abstracts
Session: 332. Antithrombotic Therapy: Poster I
Saturday, December 8, 2012, 5:30 PM-7:30 PM
Hall B1-B2, Level 1, Building B (Georgia World Congress Center)

Martin Prins, MD, PhD1*, Luke Bamber2*, Stefan Cano3*, Maria Wang4*, Anthonie WA Lensing5* and Rupert Bauersachs6*

1Clinical Epidemiology and Technology Assessment, University Medical Center, Maastricht, Netherlands
2Bayer Pharma AG, Wuppertal, Germany
3Department of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, Plymouth, United Kingdom
4Bayer Healthcare, Montville, NJ
5Bayer HealthCare AG, Wuppertal, Germany
6Department of Vascular Medicine,, Klinikum Darmstadt GmbH, Darmstadt, Germany

Background: Rivaroxaban treatment for symptomatic venous thromboembolism does not require routine laboratory monitoring, dose adjustments, or bridging with a parenteral anticoagulant and thus has the potential to reduce patient treatment burden compared with standard of care. It is becoming increasingly important to consider the views of patients in treatment decisions to improve adherence and, consequently, health outcomes. We investigated patient-reported outcomes in the EINSTEIN PE study, a large, open-label, randomized trial of patients with acute symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis. This trial compared oral rivaroxaban with dose-adjusted enoxaparin overlapping with, and followed by, vitamin K antagonist (VKA) treatment.

Methods: As part of the EINSTEIN PE study, 2397 patients from 7 countries (Canada, France, Germany, Italy, Netherlands, UK, and USA) were requested to complete a newly developed and validated measure of anticoagulation treatment satisfaction – the Anti-Clot Treatment Scale (ACTS) – at scheduled visits during treatment: Day 15, then at Months 1, 2, 3, 6, and 12. The ACTS consists of 2 scales: ACTS Burdens (12 items, scored on a 12–60 scale) and ACTS Benefits (3 items, scored on a 3–15 scale). The ACTS Burdens scale captures the negative aspects of patients’ anticoagulation experience (e.g. hassle/inconvenience, worry/frustration, and activity limitations), whereas the ACTS Benefits scale records the positive aspects (e.g. confidence, reassurance, and satisfaction). For each scale, higher total scores indicate better acceptance. In addition, patients completed the Treatment Satisfaction Questionnaire for Medication version II (TSQM II) at Months 1, 3, 6, and 12, primarily as a validation benchmark for the ACTS scale. There are 4 TSQM II subscales (Effectiveness, Side-Effects, Convenience, and Global Satisfaction), all of which are scored on a 0–100 scale. A pre-specified repeated measures analysis, stratified by intended treatment duration, with time (visit) as the repeated measure factor, was used to compare ACTS Burdens and ACTS Benefits scores between treatment groups in the intention-to-treat population; the analysis was repeated for the 4 TSQM II subscales.

Results: Patients reported a lower burden and a higher perceived benefit in the rivaroxaban with higher mean ACTS scores across visits (Table). Mean ACTS Burdens scores were 55.4 versus 51.9 for rivaroxaban and enoxaparin/VKA, respectively (p<0.0001), and mean ACTS Benefits scores were 11.9 versus 11.4, respectively (p<0.001), in favorof rivaroxaban. The ACTS Burdens scores had a consistent treatment effect over time, but the difference in ACTS Benefits scores between the groups was not constant over time and showed a greater difference at Month 2 and later time points. The TSQM II scores confirmed the greater patient-reported treatment satisfaction, with higher scores shown in patients treated with rivaroxaban in all 4 subscales; the Convenience subscale had the largest difference.

Table. EINSTEIN PE: patient-reported treatment satisfaction scores (least-squares means from pre-specified repeated measures analysis)

Scale

Rivaroxaban

Enoxaparin/VKA

p-value

 

Score

n

Score

n

 

ACTS Burdens

55.4

1149

51.9

1134

<0.0001

ACTS Benefits

11.9

11.4

<0.0001

TSQM Effectiveness

73.3

1125

69.6

1107

<0.0001

TSQM Side-Effects

86.6

816

82.3

809

<0.0001

TSQM Convenience

81.6

1129

71.8

1111

<0.0001

TSQM Global Satisfaction

80.7

1126

73.0

1109

<0.0001

Conclusions: Patients with acute symptomatic pulmonary embolism reported a lower burden, higher perceived benefits, and improved treatment satisfaction with rivaroxaban compared with enoxaparin/VKA. The improved convenience of treatment, as perceived by patients, may contribute to increased patient acceptance of and adherence to anticoagulant treatment, with consequently improved health outcomes.

Disclosures: Prins: Bayer Healthcare: Consultancy, Honoraria. Bamber: Bayer Healthcare: Employment. Cano: Bayer Healthcare: Research Funding. Wang: Bayer Healthcare: Employment. Lensing: Bayer Healthcare: Employment.

*signifies non-member of ASH